Dr Nilanjan Ghosh speaks to ecancer in an online interview for the virtual EHA 2021 meeting on the tolerability and efficacy results from a dose-escalation study of mosunetuzumab with polatuzumab vedotin for relapsed/refractory b-cell non-Hodgkin’s lymphoma.

He reports that the side effect profile was very manageable with 50% of patients experiencing Grade 3 or 4 adverse events and with CRS incidents experienced for 9.1%

Dr Ghosh also reported that the combination was very effective, with the overall response rate for all patients at 68% and the complete response rate at 55%.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.